Abstract: A composition for alleviating symptoms associated with neurotoxicity. The composition may comprise compounds for preventing glutamate mediated neurotoxicity. The composition may include one or more of the following elements: at least one glutamate antagonist, at least one cAMP stimulating agent, at least one antioxidant, vitamin B12, at least one transporter and at least one surfactant. The composition may be used in methods for alleviating tinnitus, Ménière's Disease and/or hearing loss.

Abstract: Method of treating glaucoma in a mammal, comprising administering to the mammal an effective amount of an active water-soluble carbonic anhydrase inhibitor having the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is selected from the group consisting of H, --OH, --CN and --OCH.sub.3, R.sup.2 is methyl or a lower alkyl having from two to about 5 carbon atoms, R.sup.3 is selected from the group consisting of NHCHR.sup.4 --, R.sup.5 NHCHR.sup.4 --, R.sup.5 NHCHR.sup.4 --, ##STR2## R.sup.4 is selected from lower alkyl having from one to about five carbon atoms, or a naturally occurring amino acid side-chain, and R.sup.5 is selected from the group consisting of H, CH.sub.3 --, HCO--, CH.sub.3 CO-- and X--CH.sub.2 CO-- wherein X is a halogen atom and stereoisomers thereof.

Abstract: Compositions containing mixtures of lower alkyl nicotinate and histamine hydrochloride, particularly useful in promoting hair growth and revitalizing the hair and scalp by topical application.

Abstract: Method and formulation useful in treatment of glaucoma in a mammal wherein an effective amount of an active water soluble carbonic anhydrase inhibitor is administered, said inhibitor being a compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is selected from the group consisting of H, NH.sub.2 CH.sub.2 --, --CH(Me)NH.sub.2, --CH(NH.sub.2)CHMe.sub.2, --CH(NH.sub.2)CH.sub.2 CHMe.sub.2, --CH(NH.sub.2)CH(Me)CH.sub.2 Me, 2-pyrrolidinyl residues wherein the R.sup.1 CO-- constitutes an .alpha.-aminoacyl group, N-acetylaminoacyl derivatives and the corresponding dipeptidyl radicals wherein R.sup.1 CO-- is a dipeptidyl residue containing two amino acid residues of the formula where R.sup.1 is --CHR.sup.7 NHCOCHR.sup.8 NH.sub.2, R.sup.6 NHCHR.sup.5 --, ##STR2## and R.sup.6 NHCH.sub.2 CHR.sup.5 --; R.sup.2 is selected from the group consisting of H, alkyl having from 1 to 6 carbon atoms, alkenyl having from 2 to 6 carbon atoms, and cycloalkyl;R.sup.

Abstract: Method and formulation useful in treatment of glaucoma in a mammal wherein an effective amount of an active water soluble carbonic anhydrase inhibitor is administered, said inhibitor being a compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is selected from the group consisting of H, --OH, --CN and --OCH.sub.3 ; R.sup.2 is hydrogen or a lower alkyl having from one to about 5 carbon atoms; R.sup.3 is selected from the group consisting of HNHCHR.sup.4 --, R.sup.5 NHCHR.sup.4 --, R.sup.5 NHCHR.sup.4, CONHCR.sup.4 --, R.sup.5 NHCH.sub.2 CHR.sup.4 --, ##STR2## R.sup.4 is selected from lower alkyl having from one to about 5 carbon atoms; or a naturally occurring amino acid side chain; and R.sub.5 is selected from the group consisting of H, CH.sub.3 --, HCO--, CH.sub.3 CO-- and XCH.sub.2 CO-- wherein X is a halogen atom; and stereoisomers thereof.

Abstract: A method for the treatment of degenerative joint disease in a mammal suffering therefrom which includes administration by injection of an effective amount of a pharmaceutical composition into the arthritically afflicted joints of the mammal thereby lubricating and cushioning the joints. The composition includes acrylamide or methacrylamide polymers or copolymers thereof having a molecular weight from about 1 to about 15 million and a pharmaceutically acceptable diluent.

Abstract: An improved injectionable viscoelastic gel for use in opthalmic surgical and treatment procedures, wherein the gelling agent is a high molecular weight polyacrylamide or polymethacrylamide.

Abstract: Anti-bacterial properties are imparted to a broad spectrum of ophthalmically active compositions by the inclusion therein of a urea derivative.

Abstract: An artificial tear composition comprising a sterile, aqueous hypotonic solution of lecithin and a viscosity-adjusting agent.

Abstract: An ophthalmic solution useful for the reduction of corneal edema is provided. The preparation comprises an aqueous solution of pentahydric or hexahydric alcohols in optional combination with other eye-treating ingredients. Examples of appropriate alcohols include sorbitol, inositol, and xylitol with sorbitol being especially preferred.

Abstract: An ophthalmic solution is provided for the treatment of corneal swelling and the healing of epithelial wounds. The solution is an aqueous solution of tranexamic acid which may contain optionally, other eye-treating ingredients.

Abstract: An improved injectionable viscoelastic gel for use in opthalmic surgical and treatment procedures, wherein the gelling agent is a high molecular weight polyacrylamide or polymethacrylamide.